Kenneth K. Iwata

Symptom Burden and Healthcare Resource Use in Patients With Claudin 18.2–Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Retrospective Review

Matheus Sewastjanow-Silva, Mok Oh, Lawrence Chang, Arijit Ganguli et autres

us (code pays fourni par la source)

Strategies to Mitigate Breast-related Adverse Events in Patients with High-risk Biochemically Recurrent Prostate Cancer Receiving Enzalutamide Monotherapy: Perspectives and Challenges

Neal D. Shore, Stephen J. Freedland, Lisa G. Horvath, Joe M. O’Sullivan et autres

us, au, gb, it, be (code pays fourni par la source)

Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamide

Nicole Handa, Neal D. Shore, Matthew R. Cooperberg, Elai Davicioni et autres

us (code pays fourni par la source)

Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer

Sigrid Carlsson, Pedro C. Barata, Alan H. Bryce, Daniel J. George et autres

us, se, ch (code pays fourni par la source)

Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial

Maria Ruiz-Vico, Daniel Wetterskog, Francesco Orlando, Suparna Thakali et autres

gb, es, it, se, ru, tr, de, pl, us (code pays fourni par la source)

Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma

Rebecca Waters, Matheus Sewastjanow‐Silva, Kohei Yamashita, Ahmed Abdelhakeem et autres

us (code pays fourni par la source)

Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide in Men Undergoing Active Surveillance

Ashley E. Ross, Kenneth K. Iwata, Dina Elsouda, John Hairston et autres

us (code pays fourni par la source)

1836P Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial

M. Ruiz Vico, Daniel Wetterskog, Suparna Thakali, Francesco Orlando et autres

gb, es, it, us, se, ru, tr, pl, de (code pays fourni par la source)

Longitudinal transcriptome profiling of localized hormone-sensitive tumors in treatment-naïve ENACT patients with prostate cancer with and without enzalutamide (ENZA).

Ashley E. Ross, Neal D. Shore, Elai Davicioni, Xin Zhao et autres

us (code pays fourni par la source)

Abstract 2141: Claudin 18.2 (CLDN18.2) expression prevalence, prognostication and clinical variables in gastric and gastroesophageal junction adenocarcinoma patient samples

Matheus Da Silva Sewastjanow, Kohei Yamashita, Kenneth K. Iwata, Diarmuid Moran et autres

us (code pays fourni par la source)

Supplementary Figure Legend from Effect of Intermittent Dosing Regimens of Erlotinib on Methylnitrosourea-Induced Mammary Carcinogenesis

Ronald A. Lubet, Éva Szabó, Kenneth K. Iwata, Stanley C. Gill et autres

Supplementary Figure 1 from Effect of Intermittent Dosing Regimens of Erlotinib on Methylnitrosourea-Induced Mammary Carcinogenesis

Ronald A. Lubet, Éva Szabó, Kenneth K. Iwata, Stanley C. Gill et autres